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Abstract 
Breast cancer is one of the most common 
cancers among women and the leading cause 
of death in women between the ages of 45-60 
in most developed countries. The effi cacy of 
prevention options has been established and 
includes lifestyle modifi cations, chemopreven-
tion, and prophylactic surgery. Despite the effi -
cacy of these options, breast cancer prevention 
remains underused, resulting in avoidable mor-
bidity and mortality. Here, the main barriers to 
effective use of breast cancer prevention are 
outlined and a framework to facilitate patient-
centered and evidence-based breast cancer 
prevention decision  making is presented. The 
framework is intended to encourage a shared 
decision making approach to prevention deci-
sions, within the context of a woman’s overall 
health. The inclusion of effective lifestyle in-
terventions makes this framework relevant to 
most women, and is not exclusive to women 
at increased risk of developing breast cancer. 
Key words: Breast cancer, risk assessment, 
prevention, decision making, lifestyle interven-
tions.
 
Resumen
El cáncer de mama es uno de los canceres 
más comunes y la causa principal de muerte 
entre las mujeres de las edades de 45 a 60 
en la mayoría de los países desarrollados.  La 
efi cacia de las opciones preventivas están bien 
determinadas e incluyen modifi caciones en el 
estilo de vida, quimioprevención y cirugía pro-
fi láctica. A pesar de la efi cacia de estas opcio-
nes, los medios preventivos están infrautiliza-
dos, con resultados de morbilidad y mortalidad 
que podrían evitarse. En el presente trabajo, se 
exponen las barreras principales del uso efec-
tivo de los medios de prevención del cáncer 
de mama y se presenta un encuadre para to-
mar decisiones en la prevención del cáncer de 
mama centradas en el paciente y basado en 
datos acerca de su efi cacia. Este encuadre se 
propone para estimular una aproximación a la 
toma de decisiones compartida en el contexto 
de la salud global de la mujer. La inclusión de 
intervenciones efectivas sobre el estilo de vida 
hace que este encuadre sea relevante para la 
mayor parte de las mujeres y no sea exclusivo 
de las que tengan alto riesgo de cáncer de 
mama.
Palabras clave: Cáncer de mama, evalua-
ción de riesgo, prevención, toma de deci-
sión, intervenciones en el estilo de vida.
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Background
It is estimated that 1.3 million women 
worldwide will be diagnosed with breast 
cancer annually and over 450,000 will die 
from the disease(1). The aggregate cost of 
screening and treatment is estimated to be 
$15-20 billion yearly in the United States 
alone(2). Women who live to be 75 years 
of age have approximately one in eight 
to one in twelve chance of developing 
breast cancer, making this a disease that 
concerns all women(3). The emotional, 
fi nancial, and societal burdens of breast 
cancer are immense and efforts aimed at 
early detection and prevention are well-
founded. Early detection clearly improves 
prognosis for many women when combined 
with effective treatments. However, these 
treatments come at a price of substantial 
toxicity and fall short of ensuring a cure for 
many women. Increasingly, it is suggested 
that breast health practices include risk 
stratifi cation, targeted screening, and 
selected consideration of risk-reduction 
options(4). Risk-reducing interventions for 
breast cancer provide an opportunity for 
progress against this disease and effective 
use of these strategies is therefore a necessary 
component of any comprehensive breast 
cancer control program(5). 
Options for breast cancer prevention 
are typically used in combination with 
screening and surveillance and include 
lifestyle modifi cations, chemoprevention, 
and prophylactic surgery(6). While effective, 
these interventions are not right for all 
women; some have signifi cant quality of 
life implications and others have potential 
for side effects that range from bothersome 
to life threatening. Prevention decisions 
present diffi cult tradeoffs for patients. These 
decisions are elective and require patients 
to weigh the risks and benefi ts for each 
option. In these decisions, also termed 
“preference sensitive” decisions, patients’ 
preferences should guide decision making 
as there is not one medically recommended 
curse of action. Quality decision making in 
this environment dictates that patients be 
informed about their options and have the 
opportunity to participate in the decision 
making process. But often the status quo 
of choosing no intervention in the absence 
of a risk assessment or discussion is the 
default course of action for both patients 
and providers. In contrast, a well informed 
decision making process in the breast 
cancer prevention setting should include 
a risk assessment, followed by careful 
consideration of prevention options for 
women at increased risk. This Chapter 
outlines the current clinical challenges in 
breast cancer prevention decision making, 
and concludes with a framework for 
achieving quality decision making regarding 
breast cancer prevention in the general 
population. The framework is intended 
to encourage a shared decision making 
approach to prevention decisions, within 
the context of a woman’s overall health 
and focusing on lifestyle interventions that 
are appropriate for most women. 
Current state of decision making in 
breast cancer prevention 
Although the effi cacy of breast cancer 
prevention options has been demonstrated 
in multiple clinical trials and their use is 
clearly appropriate for selected women, 
they remain underused, resulting in 
avoidable morbidity and mortality. There 
are several reasons for this. Often women 
are not aware of their breast cancer risk 
or the risk-reducing options available to 
them(7). Similarly, physicians fi nd risk 
assessment and determining patient 
eligibility challenging in the clinical setting 
and are reluctant to recommend these 
medications for women at increased risk(8). 
Finally, patients are reluctant to take these 
medications, citing fear of side effects as 
the most common deterrent(9). One study 
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found that as few as 5% of eligible women 
accept tamoxifen therapy, while less than 
25% of women eligible for prevention 
trials have elected to enroll(10,11) . 
Additional challenges are found in 
the communication of breast cancer 
risk. Studies of women’s decisions about 
breast cancer prevention and screening 
conclude that women have a tendency 
to overestimate both their risk of breast 
cancer and the risks of side effects 
associated with prevention(12). However, 
an infl ated estimate of breast cancer risk 
is not associated with improved screening 
adherence or quality decision making. For 
example, it has been shown that women 
who have undergone prophylactic bilateral 
mastectomy had signifi cantly exaggerated 
perception of their risk at the time they 
made their decisions(13). In other situations, 
women often focus on breast cancer risk 
even though they may be at greater risk 
for other diseases such as heart disease 
or lung cancer, risks that can be reduced 
substantially through lifestyle changes. 
Conversely, some women are adamantly 
opposed to risk-reducing interventions 
due to misconceptions about side effects 
associated with available interventions, 
even if breast cancer is their most signifi cant 
health threat(14). 
These compounding factors make 
clinical discussions about breast cancer 
prevention between patient and clinician 
challenging. This setting is one in which 
effective risk assessment, clinical decision 
support, and educational tools have the 
potential to add signifi cant value. Such 
tools that are designed to educate patients, 
and support clinicians in this process can 
encourage patients and providers to make 
well informed decisions consistent with 
patient preferences and circumstances. 
Components of high quality decision 
making in breast cancer prevention 
The components of a quality decision 
making process in the breast cancer 
prevention setting including the following: 
a complete breast cancer risk assessment 
in context of overall health, discussion 
of relevant risk reduction options, and 
discussion of patient preferences regarding 
these interventions and possible outcomes 
involved. 
Breast Cancer Risk Assessment 
Based on FDA guidelines, over 10 
million women in the United States are 
estimated to be eligible for tamoxifen(15). 
However, less than 2% of those eligible 
for tamoxifen are expected to develop 
breast cancer(16), highlighting the need 
for risk stratifi cation and selective use of 
these interventions from both public health 
and patient perspectives. Inappropriate 
underuse and overuse of breast cancer risk-
reduction interventions both have negative 
public health implications. Quality decision 
making in breast cancer prevention can 
be realized by identifying appropriate 
patients for specifi c risk-reducing 
interventions based on their individual 
risk and preferences. To accomplish this, 
it is necessary to provide women with 
information concerning both their risk 
of breast cancer and likely benefi t from 
available interventions. To do this, breast 
cancer risk must be assessed in context of 
the woman’s overall health. A complete risk 
assessment should include the following: 
a breast cancer risk assessment, an overall 
health assessment, and an assessment of 
risk of treatment side effects. 
There are a number of breast cancer risk 
assessment models that can facilitate this. 
For the general population, the NCI based 
Gail risk assessment model is often used(17). 
While this model is well calibrated, it is 
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not very discriminatory; for a large group 
of women, the Gail model will successfully 
predict the expected number of breast 
cancers but it is not good at predicting 
which women will develop breast 
cancer(18). For this reason, the Gail model 
is not an ideal risk stratifi cation tool for 
individual decision making. However, this 
model is widely known, relatively easy to 
use in the clinic setting (www.cancer.gov/
bcrisktool), and there are not signifi cantly 
superior models available for the general 
population. The Women’s Health Initiative 
(WHI) model, and the Breast Cancer 
Surveillance Consortium (BCSC) model are 
risk stratifi cation models that build upon 
the Gail model inputs. These three models 
require basic data about the patient history, 
including reproductive history, a partial 
family history of cancer, biopsy history 
and results, and breast density(18,19). Each 
model has its limitations, but each is more 
informative than using no model. 
Sophisticated mathematical models 
such as BRCAPRO(20) and Tyrer-Cuzick(21) 
take into account a full family history, 
and some include additional risk factors 
found in the population models. Simpler 
tools, such as the Claus(22) and Myriad/
Frank(23) risk tables are easier to use and 
can also be used to determine the risk of 
having a BRCA1 or BRCA2 mutation and/
or the future risk of developing breast or 
ovarian cancer. These family history tools 
are typically more accurate than those for 
the general population, but are not always 
applicable to all populations of women(24). 
General Health Risk Assessment 
A summary of risk factors are found 
in Table 1. While these risk factors and 
risk models are helpful in generating 
individualized risk estimates for women, 
these estimates need to be taken in context 
of the women’s overall health. For example, 
a woman with moderate breast cancer risk 
who is at risk for diabetes and has a high 
body mass index is not the best candidate 
for chemoprevention with tamoxifen. 
There are a number of tools that can assist 
either patients or providers in assessing 
a woman’s overall heath. Below is a list 
of tools available online that can predict 
some of the most common health threats 
a woman faces. 
Table 1. Risk factors for the development of breast cancer
Strong Risk Factors
    Carrying the BRCA1 or BRCA2 gene mutation 
    Signifi cant family history of breast and or ovarian cancer 
    Atypical ductal hyperplasia(ADH)/Atypia
    Lobular carcinoma in situ (LCIS)
    Age
Moderate Risk Factors 
    Dense breast tissue
    Early exposure to radiation 
    Use of hormone replacement therapy
    High alcohol consumption
    High body mass index after menopause
Weak infl uence
    Low age at fi rst menstruation   
    High age at fi rst pregnancy
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appropriate for all women. Prophylactic 
surgery (mastectomy and oophorectomy) 
and ovarian suppression options are very 
effective risk reduction techniques, but 
usually reserved for women with the 
highest levels of risk (often women with 
BRCA mutations) and those who are 
relatively risk averse(25). Patient preferences 
in these cases commonly dictate the course 
of action women choose. 
For the general population of women 
who are at moderate to high risk, there are 
effective medications to reduce the risk of 
developing breast cancer(26). These include 
tamoxifen, raloxifene, and tibolone. Each 
has been shown to be effective, and each 
has accompanying side effects, both those 
that are mild and typically disappear after 
treatment, and those that are rare but can be 
life threatening. Because the benefi t from 
risk reduction must be balanced by the risk 
of serious side effects, these medications 
are generally considered for women whose 
risk of breast cancer is moderately elevated 
over that of the average woman. 
Tamoxifen has been shown to reduce 
the risk of breast cancer by 30-50% over 
5-10 years for women with an elevated 
risk (greater than a 1.67% fi ve year risk 
as estimated by the Gail model). However, 
potential side effects can be serious and 
include endometrial cancer, stroke, and 
pulmonary embolism(27). Certain patient 
characteristics, including age, increase the 
likelihood of tamoxifen side effects. Assessing 
the presence of these characteristics can 
improve estimates of the risk of these 
side effects and therefore improve the 
predicted net benefi ts of tamoxifen. Recent 
data indicate risk reduction may persist 
as long as 10 years, providing a positive 
net therapeutic advantage to appropriately 
selected women(27,28).
Raloxifene has also been approved 
for breast cancer risk reduction in 
postmenopausal women and exhibits a 
therapeutic effect similar to tamoxifen, 
Tools for general health assessments:
– Overall health: Your Disease Risk 
(www.yourdiseaserisk.wustl.edu)
o This website assesses an 
individual’s risk of developing 
fi ve of the most common diseases 
(cancer, diabetes, heart disease, 
stroke) and provides suggestions 
for preventing them. 
– Heart disease: Framingham Calculator 
(www.framinghamheartstudy.org/
risk/hrdcoronary.html)
o This is a risk assessment tool 
for estimating a 10-year risk 
of developing coronary heart 
disease outcomes (myocardial 
infarction and coronary death). 
This tool is designed to estimate 
risk in adults aged 20 and older 
who do not have heart disease or 
diabetes. 
– Diabetes: Diabetes PHD (www.
diabetes.org/living-with-diabetes/
complications/diabetes-phd)
o Diabetes PHD (Personal Health 
Decisions) assesses the risk of 
diabetes, heart attack, stroke, 
kidney failure, and foot and 
eye complications. It also 
determines the impact on these 
risks of a variety of health care 
interventions (losing weight, 
stopping smoking, and taking 
certain medications).
– Fractures: The FRAX® tool (www.
shef.ac.uk/FRAX)
o This tool was developed by 
WHO to assess fracture risk of 
patients.
Medical Interventions to Reduce Breast 
Cancer Risk
The options for breast cancer risk 
reduction range from invasive prophylactic 
surgeries to lifestyle interventions that are 
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though reduces breast cancer risk by only 
38%, while conferring fewer side effects. 
Raloxifene has been shown to confer 
45% less risk of uterine cancer and 25% 
less risk of thromboembolic events than 
tamoxifen(29). 
Globally, tibolone is approved to 
treat menopausal symptoms and prevent 
osteoporosis but has yet to be formally 
approved in the United States. Recently, 
surprising results have emerged from a 
placebo-controlled study designed to 
demonstrate the effi cacy of tibolone in 
reducing vertebral fractures in women with 
osteoporosis(19). Tibolone was reported to 
 reduce invasive breast cancer risk by 68%. 
However the study was prematurely halted 
due to a doubling of the risk of stroke. This 
risk was most substantial within the fi rst 
year and in women more than 70 years 
of age. 
Lifestyle Interventions to Reduce Breast 
Cancer Risk 
Increasingly, research identifi es lifestyle 
factors that contribute to breast cancer 
incidence. Consequently, modifi cation of 
these factors through lifestyle interventions 
can potentially decrease the risk of 
developing breast cancer in individual 
women. Research on these risk factors is 
growing, as is their prominence as effective 
options for women to consider when 
making decisions about breast cancer 
prevention and risk management. The 
various lifestyle interventions thought to 
reduce the risk of developing breast cancer 
in the general population are described 
below and in Table 2. 
Limit Alcohol Consumption 
One of the most well documented 
modifi able risk factors for breast cancer 
development is alcohol consumption. 
Numerous prospective studies have 
demonstrated a linear relationship between 
alcohol intake and breast cancer risk, 
suggesting an approximate 10% increase in 
relative risk for each 10-gram daily increment 
of alcohol consumption (approximately 
0.75 to 1 alcoholic drinks)(30,31). 
Refrain from Using Hormone 
Replacement Therapy 
Another important modifi able risk factor 
is postmenopausal hormone replacement 
therapy (HRT). The Women’s Health 
Initiative (WHI) randomized trial have 
found that estrogen plus progestin use 
causes a 24% increase in relative risk of 
developing breast cancer, while estrogen 
use alone does not increase risk(32). A fo llow 
up study of WHI found that in addition to an 
increased risk of developing cancer, women 
who received estrogen plus progestin HRT 
experienced more deaths attributable to 
breast cancer as well as more deaths from 
all causes when compared to women who 
received no HRT(33,34). Interestingly, the only 
reason to give progestin in combination 
with estrogen is to prevent endometrial 
cancer. This cancer however is much less 
common than breast cancer and associated 
with signifi cantly less mortality. Therefore, 
if HRT is going to be used, estrogen alone 
is a much more reasonable option. 
Maintain a Healthy Weight
Higher body mass index and weight 
gain after menopause are associated with 
higher risk of breast cancer. This risk is 
estimated to be as high as a two-fold risk(35). 
However, an inverse relationship between 
body mass index and breast cancer risk is 
found in premenopausal woman.
Engage in Physical Activity
Numerous epidemiologic studies 
have shown a reduction in the risk of 
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developing breast cancer in women who 
are physically active. Together, these studies 
suggest a risk reduction on the order of 
30-40% and has been shown for various 
activities including moderate to vigorous 
recreational activities, outdoor activities, 
and heavy physical work(36). 
Refrain from Smoking
No discourse on cancer is complete 
without mentioning smoking. However, the 
data related to smoking and breast cancer 
are confl icting; some suggest as much as 
a 25% relative increase in risk associated 
with a personal history of smoking, others 
suggest only certain subtypes of breast 
cancer may be affected, other studies show 
no affect at all(37). Regardless, smoking 
should be avoided at all costs as a general 
health improvement due to the numerous 
detrimental health effects of smoking. 
In summary, these lifestyle interventions 
are likely to benefi t breast cancer risk, but 
are also benefi cial to a woman’s overall 
health. Table 3 shows the top ten causes of 
death that a woman faces(38,39). Six of these 
top ten health threats are also thought 
to benefi t from lifestyle interventions 
that benefi t breast cancer risk. These 
healthy lifestyle interventions should be 
encouraged for all women, and particularly 
for women who are at moderate to high 
risk for breast cancer but are reluctant to 
take chemoprevention. 
Table 2. Modifi able risk factors
 Risk Factor Relative Risk References
Alcohol: Strong dose response affect, consistent across 
many observational studies
· For each 10-gram increment in alcohol 
consumption
1.10 30, 31
Hormone Replacement Therapy: Strong randomized 
controlled trial evidence
 
· Combination therapy (estrogen and progestin) 1.24 32,33
· Estrogen alone
No additional 
risk 
34
Obesity: Strong, consistent evidence across many 
observational studies
1.2 – 2 35
Physical activity: Strong evidence
·  Moderate to vigorous recreational activities 0.74 36
· Outdoor activities 0.81 36
· Heavy physical work 0.6 36
Smoking: Fair evidence 1.25  37
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Proposed Decision Framework for Breast 
Cancer Risk Reduction 
Decisions about breast cancer 
prevention begin with understanding 
what a woman’s breast cancer risk level 
is, and then determining whether this risk 
is suffi cient to alter standard screening 
recommendations or initiate a preventive 
intervention. Because this prevention 
decision is not urgent, women are able 
to take the time to become fully informed 
and thoughtfully consider the options she 
faces. To facilitate, we have developed a 
framework for integrating breast cancer 
prevention decisions within the context of 
a woman’s general health. The framework 
is designed to provide structure for 
consultations regarding breast cancer 
prevention and to assist practitioners when 
having these discussions with patients. The 
framework integrates breast cancer risk 
assessment, an overall health assessment, 
and elicitation of patient preferences to 
appropriately frame this decision. 
Framework for quality decision making 
in breast cancer prevention:
 Risk assessment in context
o Breast cancer risk assessment 
using available risk assessment 
tools
 Determine if the patient is 
at increased risk for breast 
cancer.
o Overall health assessment, 
including current health issues 
and risk of other diseases
 If the patient is at increased risk 
of breast cancer, determine 
if this risk is a priority when 
compared to other possible 
health issues she may be 
facing. 
o Risk of side effects of relevant 
risk-reducing interventions 
Table 3. Top ten health threats for women(38,39).
The following top ten health threats are impacted by the lifestyle interventions indicated below.
Health Threat
Physical 
Activity
Weight 
Control
Smoking 
Cessation
Moderate 
alcohol 
consumption
1. Heart disease 9 9 9 9
2. Cancer 9 9 9 9
3. Stroke  9 9 9 9
4. COPD 9
5. Alzheimer’s 9 9 9 9
6. Injuries 
7. Diabetes 9 9
8. Infl uenza
9. Kidney disease 9 9
10. Sepsis
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 If the patient is at increased 
risk for breast cancer and it is 
a top priority for her, determine 
if she has more than average 
risk of intervention side effects 
(i.e., clotting events, endometrial 
cancer). 
 Discussion of relevant options 
o Lifestyle interventions
 Reasonable for all women to 
consider. 
o Chemoprevention 
 Reasonable for women at 
moderate to high risk without 
signifi cant health issues or 
elevated risk of side effects to 
consider. 
o Surgical interventions
 Typically reserved for women 
at very high risk. 
 Discussion of patient preferences 
o Patient risk threshold for 
interventions
 Determine if the patient level 
of breast cancer risk meets 
her threshold for intervention. 
o Patient risk threshold for side 
effects of relevant interventions 
 Determine if the expected net 
benefi t for the patient (when 
considering the risk reduction 
and the additional risk of side 
effects) meets her threshold 
for intervention. 
o Patient willingness to engage in 
lifestyle interventions
 Determine which lifestyle 
interventions, if any, are 
appropriate and determine 
patient interest in engaging 
with any particular 
recommendation. Direct to 
any relevant support services 
if available (i.e., smoking 
cessation courses). 
Role for Decision Support Tools in Breast 
Cancer Prevention 
Working through this assessment process 
and deciding which patients have suffi cient 
risk of breast cancer and potential benefi t 
to warrant risk-reducing interventions is a 
primary obligation of both primary care 
clinicians and breast care specialists. 
In turn, patients must absorb substantial 
information concerning their breast cancer 
risk and prevention options to make well-
informed preventive treatment decisions. 
In addition, women’s preferences for 
intervention options vary widely and must 
be an integral part of decision making. It is 
therefore critical that clinicians be able to 
accurately inform patients of their risks and 
options; and, understand patients’ values 
regarding possible outcomes. 
Clinical decision aids are tools that 
can be helpful in these situations by 
educating patients and encouraging 
patient participation in decisions about 
their medical care. Typically decision aids 
provide information about available options, 
help patients clarify their preferences 
regarding the outcomes associated with 
each option, and may include support for 
communicating with their clinician. The use 
of clinical decision aids has been shown to 
be benefi cial and effective for both patients 
and clinicians. In systematic reviews, 
decision aids have improved medical 
decision-making processes by increasing 
patient knowledge, decreasing decisional 
confl ict, and encouraging patients to be 
more actively involved in their decisions 
when compared to standard care(40). A recent 
systematic review of interactive, computer-
based education programs and decision aids 
found that these tools offer a feasible means 
for patient education and are well-received 
by patients in most circumstances(41). 
Additionally, decision aids that are tailored 
to individual patients provide only the most 
relevant information, avoid unnecessary 
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confusion, and are more effective than 
general informational brochures. Interactive 
computerized decision aids display 
personalized information and can respond 
to patient feedback, offering advantages 
over non-computerized decision aids(42). 
Decision aids designed specifi cally for 
clinicians to use during a patient visit have 
been shown to improve decision making 
and treatment adherence(43). 
Clinical decision aids have been 
developed for a broad range of medical 
decisions. However, very few decision aids 
have been developed for breast cancer 
risk reduction. Most decision aids for 
breast cancer prevention are in the form of 
DVDs, CD-ROMs and written educational 
materials. The available decision aids in 
breast cancer risk reduction are designed 
for small subgroups of women such as 
women considering genetic testing or 
women already known to have a BRCA 
mutation. When considering population-
wide breast cancer risk assessment and risk 
reduction, effective decision support tools 
need to be tailored to patients’ individual 
breast cancer risks and other health 
characteristics, suitable for a the general 
population by including the body of 
evidence on effective lifestyle interventions, 
and they need to actively encourage 
communication between clinicians and 
patients about patient assessed risk and 
preferences. 
There are a few decision support tools 
that fall into this category and are tools 
that can automate the breast cancer risk 
assessment process, guide providers about 
the relative priority of an individual’s breast 
cancer risk, provide individually tailored 
risk projections, and discuss possible 
options for risk reduction. Such tools 
are needed to effectively communicate 
the necessary information for informed 
decision making regarding breast cancer 
risk reduction. Tools available to do this 
include: 
 CancerGene (www4.
utsouthwestern.edu/breasthealth/
cagene)
 Hughes riskApps™ (www.
hughesriskapps.com) 
 Breast Health Decisions (www.
breasthealthdecisions.org). 
Summary and Conclusions
Breast cancer risk-reduction interventions 
have the potential to substantially decrease 
the incidence of the disease, yet remain 
underused. With millions of women are 
at some level of increased risk and could 
benefi t, there is a distinct opportunity 
to improve health outcomes by helping 
women with decision making. While 
these interventions hold the potential to 
substantially decrease the incidence of the 
disease, treating all patients the same is not 
the most effective option. Methods to stratify 
women by their risk of disease and the 
potential benefi t of prevention interventions 
are necessary to guide appropriate use of 
prevention. Similarly, patient preferences 
need to be a main driver of these decisions. 
There is a clear need for a process that 
can facilitate the often challenging tasks of 
risk assessment, risk communication, and 
preference elicitation in the clinical setting. 
The framework is intended to encourage an 
evidence based, patient-centered approach 
to breast cancer prevention decisions that 
can guide such processes. 
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